| ￥1200 | |
| A04747-50 | |
|
|
|
|
|
|
|
|
|
| Specificity | This product is specific to NAIP |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human NAIP |
| Species Reactivity | Human |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||
|
|||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
Western blot analysis of NAIP expression in Human fetal kidney lysate. »
| Target Background | Prevents motor-neuron apoptosis induced by a variety of signals. Possible role in the prevention of spinal muscular atrophy that seems to be caused by inappropriate persistence of motor-neuron apoptosis: mutated or deleted forms of NAIP have been found in individuals with severe spinal muscular atrophy. |
| Synonyms | BIRC1; Birc1a; NAIP; Naip1; NLRB1; psiNAIP; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
